Wegovy for obesity: Eligibility, Coverage, FDA Status 2026

Q: Is Wegovy approved for obesity?

FDA-approved. FDA-approved for chronic weight management at BMI ≥30, or ≥27 with a comorbidity, plus cardiovascular risk reduction.

The short answer

Wegovy and Zepbound are FDA-approved for chronic weight management; Ozempic and Mounjaro are used off-label for weight loss but are the diabetes brands.

Wegovy specifically

FDA-approved for chronic weight management at BMI ≥30, or ≥27 with a comorbidity, plus cardiovascular risk reduction.

BMI & eligibility

The on-label obesity criterion is BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA, cardiovascular disease).

Check your BMI

BMI calculator

Height (cm)Weight (kg)

Overweight27.7

BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).

BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.

Insurance & coverage

Obesity coverage is inconsistent — many commercial plans exclude weight-loss drugs entirely. When covered, prior authorization needs BMI, a comorbidity, and documented lifestyle intervention. Cash-pay and compounded routes are common.

Check if your plan covers it

We earn affiliate commissions from listed providers. See our editorial standards.

Other GLP-1s for obesity

GLP-1 medications for obesity Ozempic for obesity Zepbound for obesity Mounjaro for obesity

Wegovy for other conditions

Wegovy for PCOS Wegovy for prediabetes Wegovy for insulin resistance Wegovy for obstructive sleep apnea Wegovy for type 2 diabetes Wegovy for fatty liver disease (MASH/NAFLD)

See all GLP-1 eligibility guides

Sources

Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.